Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04725175
Recruitment Status : Recruiting
First Posted : January 26, 2021
Last Update Posted : March 3, 2021
Sponsor:
Information provided by (Responsible Party):
Pipeline Therapeutics, Inc.

Brief Summary:
This is a randomized, double-blind study of PIPE-307 or placebo in normal healthy subjects. The study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD) study enrolling approximately 48 subjects for a total duration of 6 weeks. Part 2 will be a Multiple Ascending Dose (MAD) study enrolling approximately 24 subjects for a total duration of 7 weeks, and part 3 will be a selected SAD cohort in a fed state to evaluate the effect of food on the bioavailability of PIPE-307, enrolling approximately 8 subjects from a selected SAD cohort for a duration of 6 weeks.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: PIPE-307 Drug: Placebo oral tablet Phase 1

Detailed Description:
This is a randomized, double-blind study of PIPE-307 or placebo given as single and multiple escalating doses in normal healthy subjects. The study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD) study enrolling approximately 48 subjects for a total duration of 6 weeks. Part 2 will be a Multiple Ascending Dose (MAD) study enrolling approximately 24 subjects for a total duration of 7 weeks, and part 3 will be a selected SAD cohort in a fed state to evaluate the effect of food on the bioavailability of PIPE-307, enrolling approximately 8 subjects from a selected SAD cohort for a duration of 6 weeks. Safety will be assessed by periodic measurement of vital signs, physical examinations, electrocardiograms, blood laboratory analyses and occurrence of adverse events (AE).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Masking Description: All roles are masked with the exception of the pharmacist/dose preparer.
Primary Purpose: Treatment
Official Title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE-307 and Food Effect in Normal Healthy Volunteers
Actual Study Start Date : February 26, 2021
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PIPE-307 Drug: PIPE-307
Single and multiple ascending oral doses of PIPE-307 tablets

Placebo Comparator: Placebo Drug: Placebo oral tablet
Single and multiple ascending oral doses of matching Placebo tablets




Primary Outcome Measures :
  1. Safety: Treatment-Emergent Adverse Events (TEAE) [ Time Frame: From baseline to 7 days post dosing for SAD cohorts and 21 days post dosing for MAD cohorts ]
    Number of participants with TEAEs


Secondary Outcome Measures :
  1. Safety: Cardiac repolarization using Fridericia-corrected QT interval (QTcF) [ Time Frame: From baseline to 14 days post dose for SAD cohorts and 21 days post last dose for MAD cohorts ]
    Change in mean QTcF

  2. Pharmacokinetics (PK): Blood concentration levels of PIPE-307 [ Time Frame: From baseline to 14 days post dose for SAD cohorts and 21 days post last dose for MAD cohorts ]
  3. PK: Urine concentration levels of PIPE-307 [ Time Frame: From baseline on day 1 through day 2 for SAD cohorts, and from baseline on day 1 though day 7 for the MAD cohorts ]
  4. Exploratory: Impact of PIPE-307 on Cogstate [ Time Frame: From baseline to day 2 for SAD cohorts and from baseline to day 7 for MAD cohorts ]
    Cogstate tests have been designed, developed and validated to both identify and measure cognitive impairment, and to track or monitor cognitive changes. The tasks use novel visual and verbal stimuli to ensure assessment is cultural-neutral and not limited by a participant's level of education.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female between 18 and 55 years of age (inclusive) at time of signing informed consent.
  • BMI is between 18.0 and 32.0 kg/m2
  • Male or female subjects with reproductive potential agree to comply with protocol-approved double barrier contraceptive method 30 days prior to first dose and up to 90 days post last dose
  • Medically healthy with no clinically significant or relevant abnormalities in medical history physical exam, vital signs, electrocardiogram (ECG), or laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the Investigator.

Exclusion Criteria:

  • Has a current or recurrent diseases that could affect the investigational medicinal product or affect clinical or laboratory assessments
  • Experienced a significant systemic illness, as judged by the Investigator, within 30 days of the first dose
  • Has a history of a significant medical, including hepatic and/or renal disease as outlined in the protocol, or psychiatric disorder that may require treatment or make the participant unlikely to fully complete the study or increase risk to the participant.
  • History of alcohol or other substance abuse within the 12 months prior to dosing at the discretion of the Investigator
  • Routine alcohol consumption meeting or exceeding protocol limits
  • History of prior malignancy (except adequately treated non-melanoma skin cancer, carcinoma I-situ of the uterine cervix, ductal carcinoma in situ (DCIS), or localized prostate cancer
  • Donated or lost more than 400ml of blood within 56 days or plasma within 14 days prior to screening
  • Received an investigational agent with the last 30 days prior to dosing or within 5 half-lives of the investigational agent
  • Use of any prescription medication, over-the-counter medication, vitamin or supplement, herbal or homeopathic preparations with 7 days or 5 half-lives prior to study drug administration, as determined by the Investigator. Hormone replacement therapy and hormonal contraception is permissible throughout the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04725175


Contacts
Layout table for location contacts
Contact: Deb Jezior 858-254-8480 djezior@pipeline-tx.com
Contact: Julie Iwashita jiwashita@pipeline-tx.com

Locations
Layout table for location information
Australia, Western Australia
Linear Clinical Research Recruiting
Nedlands, Western Australia, Australia, 6009
Principal Investigator: Peter Schrader, MD         
Sponsors and Collaborators
Pipeline Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Stephen Huhn, MD Chief Medical Officer, Pipeline Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Pipeline Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04725175    
Other Study ID Numbers: PIPE-307-101
First Posted: January 26, 2021    Key Record Dates
Last Update Posted: March 3, 2021
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases